www.fdanews.com/articles/122931-seattle-genetics-terminates-collaboration-with-genentech-for-dacetuzumab
Seattle Genetics Terminates Collaboration With Genentech for Dacetuzumab
December 11, 2009
Seattle Genetics, Inc. reported that it has been notified by
Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab
(SGN-40).
Earth Times
Earth Times